Mirum Pharmaceuticals Inc (MIRM) - Total Liabilities
Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has total liabilities worth $648.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mirum Pharmaceuticals Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Mirum Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Mirum Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ENN Energy Holdings Limited
F:XGH
|
Germany | €51.94 Billion |
|
Fluor Corporation
NYSE:FLR
|
USA | $4.97 Billion |
|
Yealink Network Technology Corp Ltd
SHE:300628
|
China | CN¥818.56 Million |
|
Kion Group AG
XETRA:KGX
|
Germany | €12.72 Billion |
|
Sodexo SA
PA:SW
|
France | €11.19 Billion |
|
Wyndham Hotels & Resorts Inc
NYSE:WH
|
USA | $3.80 Billion |
|
SDIC Essence Holdings Co Ltd
SHG:600061
|
China | CN¥324.54 Billion |
|
Mohawk Industries Inc
NYSE:MHK
|
USA | $5.41 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Mirum Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MIRM company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mirum Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Mirum Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $528.12 Million | +18.65% |
| 2024-12-31 | $445.11 Million | +11.85% |
| 2023-12-31 | $397.95 Million | +88.72% |
| 2022-12-31 | $210.87 Million | +20.88% |
| 2021-12-31 | $174.44 Million | +153.66% |
| 2020-12-31 | $68.77 Million | +320.27% |
| 2019-12-31 | $16.36 Million | -73.73% |
| 2018-12-31 | $62.30 Million | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more